Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable

Veena Kochat1,2, Ayush T Raman2,3,4, Sharon M Landers1

  • 1Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Acta Neuropathologica
|July 20, 2021
PubMed

Insights

Loss of Polycomb Repressor Complex 2 (PRC2) in malignant peripheral nerve sheath tumors (MPNSTs) drives a dedifferentiated neural crest state. This phenotype, targetable by enhancer blockade, distinguishes MPNSTs from neurofibromas.

Area of Science:

  • Oncology
  • Epigenetics
  • Developmental Biology

Background:

  • Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas.
  • Genetic alterations in Polycomb Repressor Complex 2 (PRC2) components (SUZ12, EED) are common in MPNSTs.

Purpose of the Study:

  • To investigate the functional consequences of PRC2 loss in MPNSTs.
  • To identify therapeutic targets associated with PRC2-mutant MPNSTs.

Main Methods:

  • Comparative analysis of PRC2-mutant and PRC2-wild-type MPNSTs.
  • Chromatin state profiling and epigenomic analysis.
  • Cross-species comparative analysis using MPNST models.
  • Functional validation using epigenetic editing and bromodomain inhibitors.

Main Results:

  • PRC2 loss induces a dedifferentiated early neural crest phenotype specific to MPNSTs.
  • Epigenomic reprogramming involves gains of active enhancers on neural crest regulators in PRC2-mutant MPNSTs.
  • Enhancer activity, particularly on DLX5, is functionally critical for the neural crest phenotype.
  • Bromodomain inhibitors targeting enhancer activity suppressed tumor growth in PRC2-mutant models.

Conclusions:

  • PRC2-mutant MPNSTs accumulate a dedifferentiated neural crest-like state.
  • Targeting enhancer activity represents a potential therapeutic strategy for PRC2-mutant MPNSTs.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.4K
Introduction to Nuclear Reprogramming01:14

Introduction to Nuclear Reprogramming

Nuclear reprogramming is the process of switching gene expression of one cell type to that of another cell type, usually from a differentiated cell state to an undifferentiated cell state. Differentiation occurs during processes such as development and morphogenesis, tissue regeneration, and malignancy. Cells can also be artificially induced to reprogram their gene expression by techniques such as nuclear transfer, induced pluripotency, and cell fusion. Such techniques have many applications in...
2.1K